Cargando…

Nifuroxazide boosts the anticancer efficacy of palbociclib-induced senescence by dual inhibition of STAT3 and CDK2 in triple-negative breast cancer

Though palbociclib, a cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor has been approved for treating breast cancer, two major clinical challenges remain: (i) Triple-negative breast cancer (TNBC) appears to be more resistant to palbociclib, and (ii) Palbociclib-induced senescence-associated secre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Xianzhe, Shi, Wei, Wang, Xumei, Lu, Jin-Jian, He, Ping, Zhang, Hongjie, Chen, Xiuping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10522654/ https://www.ncbi.nlm.nih.gov/pubmed/37752122 http://dx.doi.org/10.1038/s41420-023-01658-w

Ejemplares similares

Indisulam synergizes with palbociclib to induce senescence through inhibition of CDK2 kinase activity
por: Pogacar, Ziva, et al.
Publicado: (2022)

Combined CDK2 and CDK4/6 Inhibition Overcomes Palbociclib Resistance in Breast Cancer by Enhancing Senescence
por: Pandey, Kamal, et al.
Publicado: (2020)

The CDK4/6 Inhibitor Palbociclib Inhibits Estrogen-Positive and Triple Negative Breast Cancer Bone Metastasis In Vivo
por: Saleh, Lubaid, et al.
Publicado: (2023)

Inhibition of Stat3 signaling pathway by nifuroxazide improves antitumor immunity and impairs colorectal carcinoma metastasis
por: Ye, Ting-Hong, et al.
Publicado: (2017)

Overexpression of miRNA-3613-3p Enhances the Sensitivity of Triple Negative Breast Cancer to CDK4/6 Inhibitor Palbociclib
por: Yu, Yuanhang, et al.
Publicado: (2020)

Correction: Inhibition of Stat3 signaling pathway by nifuroxazide improves antitumor immunity and impairs colorectal carcinoma metastasis
por: Ye, Ting-Hong, et al.
Publicado: (2019)

Unexpected toxicity of CDK4/6 inhibitor palbociclib and radiotherapy
por: van Aken, Evert S. M., et al.
Publicado: (2021)

Nifuroxazide induces apoptosis and impairs pulmonary metastasis in breast cancer model
por: Yang, F, et al.
Publicado: (2015)

Nifuroxazide exerts potent anti-tumor and anti-metastasis activity in melanoma
por: Zhu, Yongxia, et al.
Publicado: (2016)

Therapeutic effects of STAT3 inhibition by nifuroxazide on murine acute graft graft-vs.-host disease: Old drug, new use
por: Jia, Huijie, et al.
Publicado: (2017)

Severe Cellular Immunodeficiency Triggered by the CDK4/6 Inhibitor Palbociclib
por: Guillaume, Zoé, et al.
Publicado: (2020)

Design, synthesis, and anticancer activity of three novel palbociclib derivatives
por: Li, Tian, et al.
Publicado: (2022)

The Combination of the CDK4/6 Inhibitor, Palbociclib, With the Vitamin D(3) Analog, Inecalcitol, Has Potent In Vitro and In Vivo Anticancer Effects in Hormone-Sensitive Breast Cancer, But Has a More Limited Effect in Triple-Negative Breast Cancer
por: Vanhevel, Justine, et al.
Publicado: (2022)

Analysis of the selection of CDK4/6 inhibitors based on experience using palbociclib
por: Kikuchi, Mariko, et al.
Publicado: (2019)

Nifuroxazide ameliorates pulmonary fibrosis by blocking myofibroblast genesis: a drug repurposing study
por: Gan, Cailing, et al.
Publicado: (2022)

Novel sequential treatment with palbociclib enhances the effect of cisplatin in RB-proficient triple-negative breast cancer
por: Huang, Yajing, et al.
Publicado: (2020)

HSulf-1 and palbociclib exert synergistic antitumor effects on RB-positive triple-negative breast cancer
por: Chen, Fengxia, et al.
Publicado: (2020)

Author Correction: Nifuroxazide exerts potent anti-tumor and anti-metastasis activity in melanoma
por: Zhu, Yongxia, et al.
Publicado: (2022)

Arctigenin inhibits STAT3 and exhibits anticancer potential in human triple-negative breast cancer therapy
por: Feng, Tingting, et al.
Publicado: (2016)

Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences
por: Braal, C. Louwrens, et al.
Publicado: (2020)

Novel therapeutic strategy for melanoma based on albendazole and the CDK4/6 inhibitor palbociclib
por: Zhu, Lin, et al.
Publicado: (2022)

Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer
por: Lu, Janice
Publicado: (2015)

Stromal Senescence following Treatment with the CDK4/6 Inhibitor Palbociclib Alters the Lung Metastatic Niche and Increases Metastasis of Drug-Resistant Mammary Cancer Cells
por: Gallanis, Gregory T., et al.
Publicado: (2023)

Nifuroxazide Mitigates Angiogenesis in Ehlrich’s Solid Carcinoma: Molecular Docking, Bioinformatic and Experimental Studies on Inhibition of Il-6/Jak2/Stat3 Signaling
por: El-Sherbiny, Mohamed, et al.
Publicado: (2021)

Open Clinical Trial on Using Nifuroxazide Compared to Probiotics in Treating Acute Diarrhoeas in Adults
por: Begovic, Begler, et al.
Publicado: (2016)

ALDH1 Bio-activates Nifuroxazide to Eradicate ALDH(High) Melanoma-Initiating Cells
por: Sarvi, Sana, et al.
Publicado: (2018)

Nifuroxazide ameliorates lipid and glucose metabolism in palmitate-induced HepG2 cells
por: Liu, Jing-Yi, et al.
Publicado: (2019)

Nifuroxazide Activates the Parthanatos to Overcome TMPRSS2:ERG Fusion-Positive Prostate Cancer
por: Li, Chengxun, et al.
Publicado: (2023)

The Existing Drug Nifuroxazide as an Antischistosomal Agent: In Vitro, In Vivo, and In Silico Studies of Macromolecular Targets
por: Roquini, Vinícius, et al.
Publicado: (2023)

DNA minicircles as novel STAT3 decoy oligodeoxynucleotides endowed with anticancer activity in triple-negative breast cancer
por: Casas, Geoffrey, et al.
Publicado: (2022)

CDK4/6 inhibitor palbociclib suppresses IgE-mediated mast cell activation
por: Hou, Yi-Bo, et al.
Publicado: (2019)

CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib
por: Raspé, Eric, et al.
Publicado: (2017)

Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells
por: Cretella, Daniele, et al.
Publicado: (2019)

Combining CDK4/6 inhibitors ribociclib and palbociclib with cytotoxic agents does not enhance cytotoxicity
por: Jin, Dan, et al.
Publicado: (2019)

P16 methylation increases the sensitivity of cancer cells to the CDK4/6 inhibitor palbociclib
por: Li, Paiyun, et al.
Publicado: (2019)

Potential Prospect of CDK4/6 Inhibitors in Triple-Negative Breast Cancer
por: Hu, Ye, et al.
Publicado: (2021)

Palbociclib-Induced Cellular Senescence Is Modulated by the mTOR Complex 1 and Autophagy
por: Cayo, Angel, et al.
Publicado: (2023)

A validated spectrofluorimetric method for the determination of nifuroxazide through coumarin formation using experimental design
por: El-Zaher, Asmaa Ahmed, et al.
Publicado: (2013)

Nifuroxazide Has Better Efficacy Than Probiotic Treatment in Adult Patients with Acute Diarrheal Syndrome
por: Husic-Selimovic, Azra, et al.
Publicado: (2022)

Analysis of the CDK4/6 Cell Cycle Pathway in Leiomyosarcomas as a Potential Target for Inhibition by Palbociclib
por: Böhm, Michael J., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_j1k2anloiobdv8hghtj0dl9mp1